summary: The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

ReferenceCitation: Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer DH, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL, Ogasawara S, Daniele B, Chan SL, Knox JJ, Qin S, Siegel AB, Chisamore M, Hatogai K, Wang A, Finn RS, Zhu AX. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clin Cancer Res. 2022 Jun 13;28(12):2547-2554. doi: 10.1158/1078-0432.CCR-21-3807.

evidence: open (via crossref license)

repository_institution: Ghent University - Ghent University Academic Bibliography

repository_institution: Université Libre de Bruxelles - Dépôt institutionnel de l'Université libre de Bruxelles

repository_institution: University of Illinois at Chicago - INDIGO

repository_institution: KU Leuven - Lirias

repository_normalized: LIRIAS (KU Leuven)

repositories_concat: LIRIAS (KU Leuven);PubMed Central;archive.ugent.be;dipot.ulb.ac.be;figshare.com

repositories_institution: University of Illinois at Chicago - INDIGO

ReferenceCitation: Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. Cardiovasc Intervent Radiol. 2022 Apr;45(4):405-412. doi: 10.1007/s00270-021-03031-9. Epub 2022 Feb 4.

ReferenceCitation: Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology. 2021 Jan;73 Suppl 1:137-149. doi: 10.1002/hep.31424. Epub 2020 Nov 6. No abstract available.

location_facility: Erasmus University Medical Center ( Site 0439)

location_facility: Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 0334)

location_facility: Universitaetsklinikum Leipzig ( Site 0202)

location_facility: SUN YAT-SEN UNIVERSITY CANCER CENTRE-Department of Medical Imaging and Interventional Radiology ( Si

location_facility: Hospital Universitario Puerta de Hierro ( Site 0596)

location_facility: University Medical Center New Orleans ( Site 0733)

location_facility: University Hospital, Kyoto Prefectural University of Medicine ( Site 0367)

location_facility: Administradora Country S.A. ( Site 0137)

location_facility: The Catholic University of Korea St. Mary s Hospital ( Site 0571)

location_facility: Seoul National University Bundang Hospital ( Site 0570)

location_facility: 2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0110)

location_facility: Centro de Oncología de Precisión-Oncology ( Site 0068)

location_facility: Hospital General Universitario de Valencia ( Site 0595)

location_facility: Toranomon Hospital Kajigaya ( Site 0369)

location_facility: Penn State Hershey Medical Center ( Site 0766)

location_facility: Osaka International Cancer Institute ( Site 0357)

location_facility: Xi'an International Medical Center Hospital ( Site 0860)

location_facility: Kaohsiung Medical University Hospital ( Site 0611)

location_facility: Azienda USL della Romagna-Dipartimento di Oncologia ed Ematologia ( Site 0332)

location_facility: Juntendo University Hospital ( Site 0371)

location_facility: Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0503)

location_facility: Fujian Provincial Cancer Hospital ( Site 0085)

location_facility: Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0056)

location_facility: The First Affiliated Hospital of Fujian Medical University ( Site 0089)

location_facility: Puerto Rico Medical Research Center LLC ( Site 0523)

location_facility: The First Hospital of Kunming ( Site 0124)

location_facility: Trakya University Medical Faculty Balkan Oncology Hospital ( Site 0648)

location_facility: Chonnam National University Hwasun Hospital ( Site 0572)

location_facility: Oslo Universitetssykehus Ullevål ( Site 0500)

location_facility: ASST Grande Ospedale Metropolitano Niguarda-Oncologia Falck ( Site 0331)

location_facility: Ramathibodi Hospital, Mahidol University ( Site 0628)

location_facility: Centro Hospitalar e Universitario de Coimbra ( Site 0502)

location_facility: Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 0673)

location_facility: Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0215)

location_facility: Hospital de Base de Sao Jose de Rio Preto ( Site 0043)

location_facility: Policlinico Universitario -Agostino Gemelli ( Site 0328)

location_facility: Mountain States Tumor Institute ( Site 0773)

location_facility: Mengchao Hepatobiliary Hospital of Fujian Medical University ( Site 0121)

location_facility: University of Cincinnati Medical Center ( Site 0791)

location_facility: C.H.U. de Nancy. Hopital de Brabois Adultes ( Site 0180)

location_facility: Jichi Medical University Hospital ( Site 0353)

location_facility: Nanfang Hospital of Southern Medical University ( Site 0088)

location_facility: Japanese Red Cross Osaka Hospital ( Site 0356)

location_facility: Bezmialem Vakf Üniversitesi-Oncology ( Site 0660)

location_facility: Royal Marsden NHS Foundation Trust ( Site 0694)

location_facility: Taichung Veterans General Hospital ( Site 0613)

location_facility: University of New Mexico Comprehensive Cancer Center ( Site 0805)

location_facility: Henry Ford Hospital-GI/Hepatology Research ( Site 0735)

location_facility: Communal non profit enterprise Regional Clinical Oncology Center ( Site 0669)

location_facility: The University of Tokyo Hospital ( Site 0348)

location_facility: Fundacion Cardiovascular de Colombia ( Site 0136)

location_facility: National Taiwan University Hospital ( Site 0606)

location_facility: Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0057)

location_facility: Somogy Megyei Kaposi Mór Oktató Kórház-Oncology center ( Site 0267)

location_facility: Konya Necmettin Erbakan University Medical Faculty ( Site 0652)

location_facility: Chinese People s Liberation Army Army Characteristic Medical Center ( Site 0117)

location_facility: China Medical University Hospital-Surgical Department ( Site 0610)

location_facility: Kanazawa University Hospital ( Site 0354)

location_facility: Zhongshan Hospital Fudan University (Xiamen Branch) ( Site 0133)

location_facility: Charite - Universitaetsmedizin ( Site 0204)

location_facility: Centro Hospitalar de Lisboa Central, EPE - Hosp St. Ant dos Capuchos ( Site 0505)

location_facility: UCLA Hematology/Oncology - Santa Monica ( Site 0720)

location_facility: Scripps Clinic Torrey Pines ( Site 0714)

location_facility: Peking Union Medical College Hospital ( Site 0087)

location_facility: Tianjin Third Central Hospital ( Site 0861)

location_facility: Hiroshima University Hospital ( Site 0360)

location_facility: Hadassah Ein Karem Jerusalem ( Site 0303)

location_facility: Icahn School of Medicine at Mount Sinai ( Site 0744)

location_facility: VA Caribbean Healthcare System ( Site 0524)

location_facility: Jinan University - Zhuhai People's Hospital-Intervention Department ( Site 0856)

location_facility: Fudan University Shanghai Cancer Center ( Site 0106)

location_facility: Ad-Vance Medical Research LLC ( Site 0527)

location_facility: Ankara City Hospital-Medical Oncology ( Site 0661)

location_facility: OHSU Center for Health & Healing ( Site 0746)

location_facility: Saitama Medical University Hospital ( Site 0370)

location_facility: Guangdong Provincial People s Hospital ( Site 0100)

location_facility: BP - A Beneficencia Portuguesa de São Paulo ( Site 0046)

location_facility: West China Hospital of Sichuan University ( Site 0119)

location_facility: Az Osp di Rilievo Nazionale A. Cardarelli ( Site 0329)

location_facility: Leids Universitair Medisch Centrum-Medical Oncology ( Site 0442)

location_facility: St Vincents University Hospital ( Site 0690)

location_facility: Tianjin Medical University Cancer Institute & Hospital ( Site 0098)

location_facility: Medizinische Hochschule Hannover ( Site 0200)

location_facility: The Ohio State University Wexner Medical Center ( Site 0759)

location_facility: Tongji Hospital Tongji Medical,Science & Technology ( Site 0126)

location_facility: Pusan National University Hospital ( Site 0568)

location_facility: Severance Hospital Yonsei University Health System ( Site 0564)

location_facility: Korea University Guro Hospital ( Site 0573)

location_facility: Centro Hospitalar do Porto, E.P.E. - Hospital Geral de Sto. Antonio ( Site 0504)

location_facility: Saga-Ken Medical Centre Koseikan ( Site 0363)

location_facility: Maastricht University Medical Centre ( Site 0440)

location_facility: Zhongshan Hospital Fudan University ( Site 0084)

location_facility: Inonu Universitesi Medical Fakultesi ( Site 0650)

location_facility: Houston Methodist Research Institute ( Site 0784)

location_facility: University of Kansas Cancer Center ( Site 0731)

location_facility: Jiangxi Provincial Cancer Hospital-Cancer Hospital ( Site 0134)

location_facility: Kyungpook National University Hospital ( Site 0569)

location_facility: Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico ( Site 0325)

location_facility: The Third Affiliated Hospital of Naval Medical University ( Site 0123)

location_facility: National Cancer Center Hospital East ( Site 0347)

location_facility: Hospital General Universitario Gregorio Maranon ( Site 0598)

location_facility: Zala Megyei Szent Rafael Korhaz ( Site 0265)

location_facility: Ege University Medical Faculty Tulay Aktas Oncology Hospital ( Site 0654)

location_facility: Shalimov s NI of Surgery and Transplantation ( Site 0671)

location_facility: I.E.U. Medical Point Hastanesi ( Site 0649)

location_facility: Centro Investigación del Cáncer James Lind ( Site 0064)

location_facility: Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 0333)

location_facility: Universitaetsklinikum Freiburg ( Site 0199)

location_facility: National Hospital Organization Kyushu Medical Center ( Site 0361)

location_facility: Universitaetsklinikum Hamburg-Eppendorf ( Site 0207)

location_facility: Odense Universitetshospital ( Site 0160)

location_facility: The First Affiliated Hospital of Xi an Jiaotong University ( Site 0108)

location_facility: Shizuoka Cancer Center Hospital and Research Institute ( Site 0365)

location_facility: Guangxi Medical University Affiliated Tumor Hospital-Hepatological surgery ( Site 0862)

location_facility: Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital ( Site 0345)

location_facility: Hospital Clinico San Carlos ( Site 0597)

location_facility: Centro Hospitalar de Sao Joao. EPE - Hospital de Sao Joao ( Site 0501)

location_facility: Zhujiang Hospital of Southern Medical University ( Site 0115)

location_facility: Chang Gung Medical Foundation. Linkou ( Site 0607)

location_facility: Seoul National University Hospital ( Site 0567)

location_facility: Fundacao Dr Amaral Carvalho ( Site 0050)

location_facility: Princess Alexandra Hospital ( Site 0006)

location_facility: Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0441)

location_facility: Edwards Comprehensive Cancer Center ( Site 0786)

location_facility: Arizona Oncology Associates PC- HOPE ( Site 0770)

location_facility: Aarhus Universitets hospital ( Site 0175)

location_facility: The First Affiliated Hospital of Soochow University ( Site 0120)

location_facility: Taipei Veterans General Hospital-Division of Gastroenterology & Hepatology, Department of Medicine (

location_facility: A.P.H. Paris, Hopital Henri Mondor ( Site 0179)

location_facility: Harbin Medical University Cancer Hospital ( Site 0090)

location_facility: Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0609)

location_facility: Chongqing Three Gorges Central Hospital ( Site 0859)

location_facility: Centro de Cancer Nuestra Senora de la Esperanza ( Site 0065)

location_facility: Universitaetsklinikum Halle ( Site 0213)

location_facility: Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0058)

location_facility: USC Norris Comprehensive Cancer Center ( Site 0717)

location_facility: Kagawa Prefectural Central Hospital ( Site 0364)

location_facility: Rambam Health Care Campus-Oncology Division ( Site 0305)

location_facility: Nara Medical University Hospital ( Site 0359)

location_facility: Westmead Hospital-Gastroenterology & Hepatology ( Site 0009)

location_facility: Clinica de Oncologia Reichow ( Site 0052)

location_facility: Hacettepe University Medical Faculty ( Site 0653)

location_facility: Yokohama City University Medical Center ( Site 0351)

location_facility: National Cheng Kung University Hospital ( Site 0608)

location_facility: Faculty of Medicine Siriraj Hospital ( Site 0629)

location_facility: University of Iowa Hospital and Clinics ( Site 0729)

location_facility: Hunan Provincial People's Hospital ( Site 0113)

title: A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)

location_country:
Germany
Ireland
New Zealand
Australia
Brazil
Japan
Thailand
Turkey
Chile
France
Colombia
Portugal
Hungary
Hong Kong
Denmark
United States
Ukraine
China
Puerto Rico
Italy
Norway
United Kingdom
Netherlands
Korea, Republic of
Spain
Taiwan
Israel


type: EudraCT Number

title: A Phase Ib/II, Open-Label, Multicenter Study With a Non-Randomized Stage Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab Plus Lenalidomide (+Len), and a Randomized Stage Evaluating the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Patients With Follicular Lymphoma

summary: This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of IV mosunetuzumab + len vs subcutaneous (SC) mosunetuzumab + len.

study_start_date_type: Actual

status: Active, not recruiting

study_completion_date_type: Anticipated

study_type: Interventional

design_allocation: Non-Randomized

primary_purpose: Treatment

enrollment_type: Anticipated

ipd_sharing: Yes

ipd_sharing_description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

lead_sponsor: Hoffmann-La Roche

location_country:
United Kingdom
United States
China
Spain
France

location_facility: University College London Hospitals NHS Foundation Trust - University College Hospital

location_facility: Hospital Universitario Virgen de la Victoria

location_facility: Hospital Universitario Fundacion Jimenez Diaz.

location_facility: Centre Hospitalier Lyon Sud; Direction Générale

location_facility: Nottingham University Hospitals NHS Trust - City Hospital

location_facility: Complejo Asistencial Universitario de Salamanca

location_facility: Oxford University Hospitals NHS Foundation Trust

location_facility: The First Affiliated Hospital of Xiamen University

location_facility: Tianjin Medical University Cancer Institute & Hospital

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Ongoing


title: Prospective, Open-Label Clinical Study of Andexanet Alfa in Patients Receiving FXa (Activated Factor X) Inhibitor Who Require Urgent Surgery

acronym: Annexa-S

summary: Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.

status: Terminated

study_completion_date_type: Actual

enrollment_type: Actual

ipd_sharing_description: Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

lead_sponsor: Alexion Pharmaceuticals, Inc.

location_country:
Germany
France
Japan
Austria
United States
Israel

status_simplified: Unknown


acronym: REGENCY

summary: This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids.

ReferenceType: derived

ReferenceCitation: Dossier C, Hogan J. Response to Majeranowski. Pediatr Nephrol. 2021 Jun;36(6):1653. doi: 10.1007/s00467-021-04982-4. Epub 2021 Mar 10. No abstract available.

oa_host_type: publisher

evidence: open (via free pdf)

host_type: publisher

license_normalized: no license

version: publishedVersion

repositories_concat: closed

unpaywall_oa_status: bronze

publisher_dissemination: Springer-Nature

location_facility: Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital

location_facility: NYU Langone Medical Center; Seligman Center for Advanced Therapeutics

location_facility: Groote Schuur Hospital and University of Cape Town; E13 Renal Unit & J46 Dept of Medicine

location_facility: ASST Monza - Ospedale San Gerardo; Clinica Nefrologica

location_facility: University of Utah Health Science center; Internal Medicine for the University of Utah

location_facility: Medyczne Centrum Hetmanska; Rheumatology

location_facility: Hopital Claude Huriez; Internal Medicine

location_facility: Instituto del Cerebro y la Columna Vertebral SAC

location_facility: Hospital Ramon y Cajal ; Servicio de Reumatologia

location_facility: The Ohio State University Wexner Medical Center

location_facility: Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova

location_facility: Policlinico di Bari; Divisione di Nefrologia, Dialisi e Trapianto

location_facility: SPSK Slaskiego UM w Katowicach; Katedra i Klinika Nefrologii, Endokryn.I Chorob Przemiany Materii

location_facility: ?Kazan (Privolzhsky) Federal University?; Academic Hospital

location_facility: Groupe Hospitalier Pitie-Salpetriere; Service de Medecine Interne Ii

location_facility: AD-CARE, University of Rochester Medical Center

location_facility: Universitaetsmedizin Johannes Gutenberg; Rheumatologie

location_facility: Hospital Nacional Cayetano Heredia; Rheumatology

location_facility: Universitätsklinikum "Carl Gustav Carus"; Medizinische Klinik III

location_facility: Clínica San Juan Bautista CSJB; UNIDAD DE INVESTIGACION EN REUMATOLOGIA E INMUNOLOGIA CSJB

location_facility: Azienda Ospedaliera di Padova; Dipartimento di Medicina - UOC di Reumatologia

location_facility: Hospital Clinic i Provincial; Servicio de Nefrologia

location_facility: Ser Servicos Especializados Em Reumatologia

location_facility: Centro de Investigación y Tratamiento Reumatológico S.C.

location_facility: University of Miami Miller School of Medicine

location_facility: Universitätskrankenhaus Tübingen; Innere Medizin / Hämatologie und Internistische Onkologie

location_facility: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. Prof. Eleonory Reicher

location_facility: Hopital Bichat Claude Bernard; Nephrologie

location_facility: Panaroma Medical Center; Clinical Trials Department

location_facility: Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie

location_facility: Charité Campus Mitte, Med.Klinik, Rheumatologie und Klinische Immunologie

location_facility: Federal Centre of Heart, Blood and Endocrinology n.a. V.A.Almazov; Rheumatology Department

location_facility: Kaiser Permanente - San Francisco Medical Center

location_facility: Hospital Universitario; Dr. Jose Eleuterio Gonzalez

location_facility: Azienda Ospedaliera Universitaria Careggi

location_facility: Chaim Sheba Medical Center; Rheumatology

location_facility: Centro Multidisciplinar de Estudos Clínicos - CEMEC*X*

location_facility: A.O. Spedali Civili Di Brescia-P.O. Spedali Civili; Nefrologia

location_facility: SBEI HPE "The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova"of MoH of RF

location_facility: University of Alabama at Birmingham Medical Center

location_facility: Ortopedyczno Rehab Szpital Klinic im Wiktora Degi UM; Oddzial Reumat Rehab i Chorob Wewnetrznych

location_facility: Hopital Universitaire; Nephrologie Clinique Medicale B

location_facility: Asst Degli Spedali Civili Di Brescia; Reumatologia Ed Immunologia Clinica

location_facility: Szpital Kliniczny Dzieciatka Jezus; Klinika Med. Transplantacyjnej, Nefrologii i Chorob Wew

location_facility: Hospital Universitario Vall d'Hebron; Servicio de Medicina Interna

location_facility: Ospedale ARNAS - P.O."Civico e Benfratelli; UOC Nefrologia e Dialisi

location_facility: Städtisches Klinik Dresden-Friedrichstadt; I. Medizinische Klinik

location_facility: Instituto Nacional de Ciencias Médicas Y de La Nutricion Zubirán

location_facility: Hospital das Clinicas - FMUSP Ribeirao Preto; Reumatologia

location_facility: Hospital Universitario 12 de Octubre; Servicio de Reumatologia

location_facility: HOPITAL HENRI MONDOR; SERVICE DE Nephrologie

location_facility: Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

location_facility: Hopital Rangueil; Service de Nephrologie & D'Immunologie Clinique

title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

type: Other Identifier

source: euctr

design_allocation: Randomized

location_country:
Germany
Italy
Poland
Colombia
Israel
Argentina
United Kingdom
Brazil
Mexico
United States
Spain
South Africa
Peru
Russian Federation
France


acronym: LIBERTY-BP

lead_sponsor: Regeneron Pharmaceuticals

summary:
The primary objective of the study is to demonstrate that dupilumab is superior to placebo in achieving sustained remission off oral corticosteroids (OCS) in patients with bullous pemphigoid (BP).

The secondary objectives of the study are:

To evaluate the OCS-sparing effects of dupilumab in patients with BP
To evaluate the effect of dupilumab on itch in patients with BP
To evaluate the effects of dupilumab on health-related quality of life measures in patients with BP
To evaluate the effect of dupilumab in circulating BP180 and BP230 autoantibody titers
To assess the safety and tolerability of dupilumab administered to patients with BP
To characterize the trough concentrations of functional dupilumab over time following administration of dupilumab in patients with BP
To assess the immunogenicity of dupilumab in patients with BP over time

sponsor_collaborators:
Regeneron Pharmaceuticals
Sanofi

location_facility:
Regeneron Study Site 2
Regeneron Study Site
Regeneron Study site
Regeneron Study site'
Regeneron study Site

title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

ipd_sharing_description: All individual patient data (IPD) that underlie publicly available results will be considered for sharing

location_country:
Germany
France
Poland
Australia
Japan
United States
Spain
Taiwan
Israel


lead_sponsor: Loxo Oncology, Inc.

summary: The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

ReferenceCitation: Claerhout S, Lehnert S, Vander Borght S, Spans L, Dooms C, Wauters E, Vansteenkiste J, Weynand B, Deraedt K, Bourgain C, Vanden Bempt I. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer. Lung Cancer. 2022 Apr;166:242-249. doi: 10.1016/j.lungcan.2022.02.013. Epub 2022 Mar 1.

oa_host_type: closed

publisher_dissemination: Elsevier

ReferenceCitation: Solomon BJ, Zhou CC, Drilon A, Park K, Wolf J, Elamin Y, Davis HM, Soldatenkova V, Sashegyi A, Lin AB, Lin BK, F Loong HH, Novello S, Arriola E, Perol M, Goto K, Santini FC. Phase III study of selpercatinib versus chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncol. 2021 Mar;17(7):763-773. doi: 10.2217/fon-2020-0935. Epub 2020 Nov 5.

oa_colors: green hybrid

oa_host_type: publisher;repository

evidence: open (via page says license)

license: cc-by-nc-nd

license_normalized: cc-by-nc-nd

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

repository_institution: Universitat Pompeu Fabra - Repositori digital de la UPF

repository_normalized: University of Melbourne - Minerva Access

version: submittedVersion

repository_institution: University of Turin - Institutional Research Information System University of Turin

repositories: University of Melbourne - Minerva Access

repositories_concat: University of Melbourne - Minerva Access;iris.unito.it;repositori.upf.edu

unpaywall_oa_status: hybrid

publisher_dissemination: Future Science Ltd

sponsor_collaborators:
Loxo Oncology, Inc.
Eli Lilly and Company

location_facility: Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne

location_facility: Republic Oncology Dispensary of MoH of Republic Tatarstan

location_facility: Samara Regional Clinical Oncology Center

location_facility: Taipei Medical University Shuang Ho Hospital

location_facility: Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council, "Dnipro State Medical University"

location_facility: Institut Català d'Oncologia (ICO) - Badalona

location_facility: Spitalul Clinic Judetean de Urgenta Sf.Apostol Andrei Constanta

location_facility: Icesp - Instituto Do Câncer Do Estado de São Paulo

location_facility: Institut du Cancer de Montpellier - Val d'aurelle

location_facility: Azienda Sanitaria Ospedaliera S Luigi Gonzaga

location_facility: Fundacion CENIT para la Investigacion en Neurociencias

location_facility: First Affiliated Hosp of College of Med, Zhejiang University

location_facility: First affiliated Hospital of Sun Yat-Sen University

location_facility: Soroka Medical Center - Pediatric Outpatient Clinic

location_facility: Istituto Nazionale Tumori IRCCS Fondazione Pascale

location_facility: Azienda Ospedaliera San Camillo Forlanini

location_facility: Baskent University Dr. Turgut Noyan Research and Training Center

location_facility: Hospital Universitario La Fe de Valencia

location_facility: ASST Grande Ospedale Metropolitano Niguarda

location_facility: Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

location_facility: Azienda Ospedlaliero-Univeristaria Pisana, Stabilimento Ospedaliero di Cisanello

location_facility: Chang Gung Memorial Hospital - Kaohsiung Branch

location_facility: First Moscow State Medical University n.a. Sechenov

location_facility: Centro de Oncología e Investigación de Buenos Aires

location_facility: Instituto de Educação, Pesquisa e Gestão em Saúde

location_facility: Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council"

location_facility: Izmir Ataturk Training and Research Hospital

location_facility: I.F.O. Istituto Nazionale Tumori Regina Elena

location_facility: Health Pharma Professional Research S.A. de C.V:

location_facility: Vrije Universiteit Medisch Centrum Amsterdam

location_facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

location_facility: St-Petersburg scientifical practical cente spec medical care

location_facility: Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca

location_facility: Spitalul Judetean de Urgenta "Sf. Ioan cel Nou"

location_facility: Hospital General Universitario de Alicante

location_facility: Sotiria Thoracic Diseases Hospital of Athens

location_facility: Spitalul Universitar de Urgență București

location_facility: Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology

location_facility: Nemocnice AGEL Ostrava-Vitkovice a.s.-Plicni oddeleni

location_facility: Seoul National University Bundang Hospital

location_facility: Fundação Pio XII - Hospital de Câncer de Barretos

location_facility: Harbin Medical University Cancer Hospital

location_facility: Union Hospital Tongji Medical College Huazhong University of Science and Technology

location_facility: CHU Grenoble Alpes- Hopital Albert Michallon

location_facility: Municipal Enterprise "Volyn Regional Medical Oncology Centre" of the Volyn Regional Council

location_facility: Arkhangelsk Clinical Oncological Dispensary

location_facility: Assistance Publique Hôpitaux de Marseille - Hôpital Nord

location_facility: Actualidad Basada en la Investigación del Cáncer

location_facility: University General Hospital of Heraklion

location_facility: Chernivtsi Regional Oncological Dispensary

location_facility: Inonu Universitesi Turgut Ozal Tıp Merkezi

location_facility: Xinjiang Medical University Cancer Hospital

location_facility: GBUZ Republican Clinical Oncological Dispensary

location_facility: Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital

location_facility: Peninsula & South Eastern Haematology and Oncology Group

location_facility: West China Hospital of Sichuan University

location_facility: Sumy regional clinical oncological dispensary

location_facility: Policlinico Gemelli - Università Cattolica del Sacro Cuore

location_facility: The First Affiated Hospital Of Guangzhou Medical Collage

location_facility: Hospital Clínico Universitario de Valencia

location_facility: City Hospital, Nottingham University Hospitals

location_facility: N.N.Petrov Research Institute of Oncology

location_facility: Hacettepe University Faculty of Medicine

title: LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

ipd_sharing_description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

location_country:
Germany
Poland
Argentina
Australia
Brazil
Japan
Turkey
Czechia
Canada
France
Hong Kong
Ukraine
Romania
Belgium
China
Italy
United Kingdom
Singapore
Netherlands
Mexico
Korea, Republic of
Spain
Greece
Taiwan
Russian Federation
Israel


acronym: POLARGO

summary: This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) in participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study comprises of two stages: a safety run-in stage and a randomized controlled trial (RCT).

location_facility: Tampere University Hospital; Dept of Oncology

location_facility: Severance Hospital, Yonsei University Health System

location_facility: Universitaetsklinikum Schleswig Holstein - Campus Luebeck; Haematologie, Onkologie

location_facility: Hospital Universitario Dr. Peset; Servicio de Hematologia

location_facility: McGill University Health Centre - Glen Site

location_facility: IHA Hematology Oncology Consultants - Ann Arbor; Michigan Orthopedic Center

location_facility: Laiko General Hospital; Hematology Clinic

location_facility: Institute of Hematology and Hospital of Blood Disease

location_facility: Hopital Bretonneau; Hematologie Therapie Cellulaire

location_facility: Hospital Clinico Universitario de Salamanca;Servicio de Hematologia

location_facility: Memorial Sloan Kettering Cancer Center at Westchester

location_facility: Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo.

location_facility: St James' Hospital; Cancer Clinical Trials Office

location_facility: Nottingham City Hospital; Dept of Haematology

location_facility: Gemeinschaftsklinikum Mittelrhein gGmbH; Ev. Stift St. Martin

location_facility: All India Institute of Medical Sciences ,Institute Rotary Cancer Hospital; Department of Oncology

location_facility: Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology

location_facility: Hospital Univ. 12 de Octubre; Servicio de Hematologia

location_facility: Sakarya Universitesi Egitim ve Arastirma Hastanesi

location_facility: Niagara Health Systems - St. Catherines General Site; Niagara Health System-St. Catharines Site

location_facility: First Affiliated Hospital of Medical College of Xi'an Jiaotong University

location_facility: Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny

location_facility: Nebraska Cancer Specialists; Oncology Hematology West, PC

location_facility: Guangxi Cancer Hospital of Guangxi Medical University

location_facility: Centre hospitalier regional de Trois-Rivieres

location_facility: Seoul National University Bundang Hospital

location_facility: Abdurrahman Yurtarslan Onkoloji Training and Research Hospital

location_facility: Istanbul University Cerrahpasa Medical Faculty; Hematology Department

location_facility: Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)

location_facility: Memorial Sloan Kettering Cancer Center at Bergen

location_facility: Memorial Cancer Institute at Memorial West

location_facility: Hopital De Haut Leveque; Hematologie Clinique

location_facility: West China Hospital - Sichuan University

location_facility: Instituto Nacional de Cancerologia; Oncology

location_facility: Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia

location_facility: Ematologia/immunologia Clinica Azienda Ospedaliera Policlinico di Padova

location_facility: Akdeniz Uni School of Medicine; Hematology

location_facility: Azienda Ospedaliero-Universitaria Policlinico di Modena Ematologia

location_facility: Union Hospital Tongji Medical College Huazhong University of Science and Technology

location_facility: The 1st Affiliated Hospital of Nanchang Unversity

location_facility: Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica

location_facility: Hospital de Especialidades Centro Medico Nacional La Raza; Haematology

location_facility: Centre Henri Becquerel; Service Hématologie

location_facility: Az. Osp. Uni Ria Policlinico Tor Vergata; Unita Di Ematologia

location_facility: Hospital Universitario de Canarias;servicio de Hematologia

location_facility: Amerikan HAstanesi Onkoloji Birimi Te?vikiye

title: A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX Alone in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ipd_sharing_description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing/).

location_country:
Finland
Germany
Ireland
Italy
India
United Kingdom
Brazil
Mexico
United States
China
Korea, Republic of
Spain
Greece
Turkey
Canada
France


acronym: SALTO

lead_sponsor: Actelion

summary: The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.

location_facility: Complexo de Prevencao,Diagnostico,Terapia e Reabilitacao Respiratoria LTDA Hospital Dia do Pulmao

location_facility: Severance Hospital, Yonsei University Health System

location_facility: Fundacao Universitaria de Cardiologia - Instituto de Cardiologia e Transplantes do DF

location_facility: Congenital Heart Center of the University of Florida

location_facility: Dnipropetrovsk clinical medical center of Mother and Child after prof. Rudnev

location_facility: Irmandade Santa Casa de Misericordia de Porto Alegre

location_facility: The General Hospital of Northern Theater Command

location_facility: Guangzhou Women And Children's Medical Center

location_facility: Wojewodzki Szpital Specjalistyczny we Wroclawiu

location_facility: Unidad de Investigacion Clinica en Medicina S.C. (UDICEM)

location_facility: Instytut Pomnik - Centrum Zdrowia Dziecka

location_facility: Behcet Uz Pediatric Diseases and Surgery Training and Research Hospital

location_facility: Cincinnati Children's Hospital Medical Center

location_facility: ASST Grande Ospedale Metropolitano Niguarda

location_facility: Veltischev Research and Clinical Institute for Pediatrics of the Pirogov RNRMU

location_facility: Azienda Ospedaliera Policlinico S. Orsola-Malpighi

location_facility: CAPA Istanbul University Medical Faculty

location_facility: Mehmet Akif Ersoy Training and Research Hospital

location_facility: Samara Regional Clinical Cardiological Dispensary

location_facility: New Children's Hospital of the Helsinki University Hospital (HUS)

location_facility: University of Virginia Division of Pediatric Cardiology

location_facility: Irmandade Santa Casa de Misericordia de Sao Paulo

location_facility: Vilnius University Hospital Santariskiu Clinics

location_facility: AOU Città della Salute e della Scienza di Torino, Presidio Ospedale Infantile Regina Margherita

location_facility: SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo

location_facility: Pusan National University Yangsan Hospital

location_facility: Cardiovascular Pathology Research Institute of Siberian Branch of RAMS

location_facility: State Institution Republican Scientific And Practical Center For Pediatric Surgery

location_facility: Izmir Tepecik Training and Research Hospital

location_facility: Childrens City Clinical Hospital n.a. Bashlyaeva

location_facility: Uniwersytecki Szpital Dzieciecy w Krakowie

location_facility: Gottsegen György Országos Kardiológiai Intézet

location_facility: Operadora de Hospitales Angeles SA de CV Hospital Angeles Lomas

location_facility: Health Institution 4Th City Children'S Clinical Hospital

location_facility: Centre Hospitalier Universitaire Vaudois (CHUV)

location_facility: Drottning Silvias barn- och ungdomssjukhus

location_facility: Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead

location_facility: Secretaria da Saude do Estado do Ceara - Hospital Doutor Carlos Alberto Studart Gomes

location_facility: University Medical Center Ho Chi Minh city

location_facility: Scientific Practical Medical Center for Pediatric Cardiology and Cardio Surgery of the MOH

location_facility: MI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiac Surgery'

location_facility: MI Zaporizhzhia Regional Clinical Childrens Hospital of Zaporizhzhia Regional Council

location_facility: Cukurova Balcali Hospital Application and Research Center

title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged >=2 to <18 Years With Pulmonary Arterial Hypertension

type: Registry Identifier

ipd_sharing_description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu

location_country:
Finland
Germany
Ireland
Poland
Australia
Brazil
Thailand
Vietnam
Turkey
Canada
Serbia
France
Belarus
Lithuania
Colombia
Portugal
Hungary
Switzerland
United States
Ukraine
Belgium
China
Malaysia
Italy
Sweden
Mexico
Korea, Republic of
Spain
Taiwan
Bulgaria
Russian Federation
Israel


title: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

summary: To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC). For more information, please visit https://www.cardio-ttransform.com.

ipd_sharing: No

lead_sponsor: Ionis Pharmaceuticals, Inc.

location_country:
Germany
Poland
Argentina
Australia
Brazil
Japan
Czechia
Canada
France
Portugal
Denmark
United States
Belgium
Puerto Rico
Italy
United Kingdom
Sweden
Austria
Spain
Greece
Israel

location_facility: The George Washington Medical Faculty Associates - Foggy Bottom North Pavilion

location_facility: Centro Hospitalar Universitário de Lisboa Central - Hospital de Santa Marta

location_facility: Gordon and Leslie Diamond Health Care Centre

location_facility: Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto

location_facility: Synexus - Merseyside Clinical Research Centre

location_facility: Hospital da Senhora da Oliveira - Guimarães

location_facility: Synexus - North Tees Clinical Research Centre

location_facility: Centre Hospitalier de l'Université de Montréal (CHUM)

location_facility: Hospital of the University of Occupational and Environmental Health

location_facility: Narodowy Instytut Kardiologii Stefana kardyna Wyszyskiego - Pastwowy Instytut Badawczy

location_facility: University Hospital Kyoto Prefectural University of Medicine

location_facility: New York University Langone Cardiology Associates

location_facility: Azienda Ospedaliero - Universitaria Careggi

location_facility: Froedtert & Medical College of Wisconsin

location_facility: The University of North Carolina at Chapel Hill

location_facility: University of Texas Southwestern Medical Center

location_facility: Krakowski Szpital Specjalistyczny im. Jana Pawa II

location_facility: Centro Hospitalar Universitário de São João

location_facility: University Hospitals Cleveland Medical Center

location_facility: Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanita Pubblica

location_facility: The Westmead Institute for Medical Research

location_facility: Instituto Dante Pazzanese de Cardiologia

location_facility: Complejo Hospitalario Universitario de Santiago

location_facility: Louisiana State University Health Sciences Center

location_facility: Synexus Midlands Clinical Research Centre

location_facility: Ziekenhuis Oost-Limburg - Campus Sint-Jan

location_facility: Carl and Edyth Lindner Research Center at The Christ Hospital

location_facility: Synexus - Scotland Clinical Research Centre

location_facility: University Hospital - London Health Sciences Centre

location_facility: Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona

location_facility: Altman Clinical and Translational Research Institute Center for Clinical Research

location_facility: Centro Avançado de Pesquisa e Estudos para o Diagnóstico CAPED

location_facility: University of Colorado Hospital - Anschutz Medical Campus

location_facility: Universitaetsklinikum Heidelberg - Zentrum fur Innere Medizin

location_facility: A Beneficência Portuguesa de São Paulo - Unidade Mirante

location_facility: Centro Hospitalar Universitário do Porto - Hospital Geral de Santo Antonio

location_facility: University of California, San Francisco (UCSF) - Medical Center

location_facility: Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan

location_facility: Hospital Universitario Puerta de Hierro - Majadahonda

location_facility: The University of Chicago Medical Center

location_facility: Veterans Affairs Caribbean Healthcare System

location_facility: Hospital Clínico Universitario Virgen de la Arrixaca

location_facility: The Ohio State University College of Medicine

location_facility: Institut Klinické a Experimentální Medicíny

location_facility: Centre Hospitalier Universitaire De Nantes - Hôpital Nord Laennec

location_facility: Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant Orsola-Malpighi

location_facility: Synexus - Manchester Clinical Research Centre

location_facility: Tulane University Heart and Vascular Institute

location_facility: Emory Heart and Vascular Center - Emory Clifton Campus

location_facility: Instituto Cardiovascular de Buenos Aires

location_facility: Azienda Ospedaliera - Universitaria Sant' Andrea

location_facility: Columbia University Irving Medical Center


title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)

acronym: SS

summary: The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).

status: Completed

lead_sponsor: Viela Bio (acquired by Horizon Therapeutics)

location_country:
Italy
Poland
India
Hungary
Argentina
United Kingdom
Mexico
United States
Korea, Republic of
Taiwan
Peru
France

location_facility:
Research site
Research Site

status_simplified: Completed


lead_sponsor: Janssen Research & Development, LLC

summary: The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

ReferenceCitation: Liu AP, Cheuk DK. Disease-modifying treatments for primary autoimmune haemolytic anaemia. Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD012493. doi: 10.1002/14651858.CD012493.pub2.

oa_host_type: repository

evidence: oa repository (via OAI-PMH title and first author match)

evidence: oa repository (via pmcid lookup)

repository_normalized: PubMed Central

repositories_concat: PubMed Central;hub.hku.hk

unpaywall_oa_status: green

publisher_dissemination: Wiley

location_facility: The First Affiliated Hospital of Xi'an Jiaotong University

location_facility: Tianjin Medical University General Hospital

location_facility: Scotland Cancer Treatment Center - Duke Cancer Network

location_facility: Hospital Universitario Puerta de Hierro Majadahonda

location_facility: Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico

location_facility: University of Wisconsin Carbone Cancer Center

location_facility: East Carolina University-School of Medicine

location_facility: Attikon University General Hospital of Attica

location_facility: Oxford University Hospitals NHS Foundation Trust

location_facility: Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4

location_facility: Kyiv City Clinical Hospital #9, Department of infectious diseases

location_facility: University General Hospital of Thessaloniki

location_facility: Ternopil University Hospital of Ternopil Regional Council

location_facility: The First Affiliated Hospital of Soochow University

location_facility: University Hospital Southampton NHS Foundation Trust

location_facility: Universita Cattolica del Sacro Cuore - Fondazione Policlinico Universitario 'A. Gemelli'

location_facility: University of Colorado - Anschutz Medical Campus

location_facility: Hematology Oncology Associates of Rockland

location_facility: Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi

location_facility: Huashan Hospital affiliated to Fudan University

location_facility: Rabin Medical Center, Beilinson Hospital

location_facility: Japan Community Health care Organization Kyushu Hospital

location_facility: Affiliated Hospital of Nantong University

location_facility: The Ohio State University- James Cancer Hospital

location_facility: University General Hospital of Rio Patras

location_facility: Cherkassy Regional Oncology Dispensary, Department of Hematology

location_facility: Università del Piemonte Orientale - Ospedale Maggiore della Carità di Novara

location_facility: Taussig Cancer Insititute - Cleveland Clinic

location_facility: First Affiliated Hospital, Medical School of Zhejiang University

location_facility: Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet, Szent László Telephely

location_facility: Guangzhou First Municipal People's Hospital

location_facility: University of Florida Health Jacksonville

location_facility: Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi

location_facility: Centro Integrado de Pesquisa -Hospital de Base de São José do Rio Preto

location_facility: Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'

location_facility: Beijing Chao-yang Hospital, Capital Medical University

location_facility: West China Hospital of Sichuan University

location_facility: Hospital of the University of Pennsylvania

location_facility: Klinika Hematologii i Transplantologii, UCK

location_facility: Hospital Das Clinicas Da Faculdade De Medicina Da USP

location_facility: General Hospital of Athens 'G. Gennimatas'

status: Recruiting

title: Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label Extension

location_country:
Germany
Italy
Poland
Hungary
Israel
United Kingdom
Japan
Brazil
Netherlands
United States
China
Korea, Republic of
Spain
Greece
Malaysia
Czechia
Ukraine
France


title: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

summary: This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in participants with relapsed and frontline CD123-positive AML.

lead_sponsor: ImmunoGen, Inc.

location_country:
Germany
Italy
United Kingdom
United States
Spain
France

location_facility: Oxford University Hospital - Churchill Hospital

location_facility: Hospices Civils de Lyon, Lyon-Sud Hospital

location_facility: Roswell Park Comprehensive Cancer Center

location_facility: Mayo Clinic Hospital - Rochester St. Mary's Campus

location_facility: Istituto di Ematologia "Lorenzo e A. Seragnoli" - Policlinco S. Orsola - Malpighi

location_facility: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)

location_facility: Hospital Universitario y Politécnico de La Fe

location_facility: Azienda Ospedaliera Universitaria Maggiore Della Carita Novara

location_facility: Robert H. Lurie Comprehensive Cancer Center of Northwestern University

location_facility: City of Hope Comprehensive Cancer Center


title: A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

summary:
The primary objective of the dose escalation (phase 1) part of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of REGN5093 for determination of the maximum tolerated dose (MTD) and/or definition of the recommended phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung cancer (NSCLC).

The primary objective of the dose expansion (phase 2) part of the study is to assess preliminary anti-tumor activity of REGN5093 as measured by the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

ipd_sharing_description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

location_country:
United States
Korea, Republic of
France

location_facility:
Regeneron Study Site
Regeneron Research Facility


lead_sponsor: Amgen

summary: This is a phase 2, open-label, single-arm, multicenter clinical trial designed to evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior anti-programmed cell death protein (anti-PD-1) therapy in unresectable/metastatic melanoma (stage IIIB-IVM1d) or prior anti-PD-1 therapy in the adjuvant setting. Subjects will be treated with talimogene laherparepvec and pembrolizumab until confirmed complete response, disappearance of all injectable lesions, documented confirmed disease progression per modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST), intolerance of study treatment, or 102 weeks from the first dose of talimogene laherparepvec and/or pembrolizumab, whichever occurs first.

sponsor_collaborators:
Amgen
Merck Sharp & Dohme LLC

location_facility: Hospital Universitario Madrid Sanchinarro

location_facility: Hospital Clinico Universitario Virgen de la Victoria

location_facility: University of Florida Health Cancer Center at Orlando Health

location_facility: Nederlands Kanker Instituut, Antoni van Leeuwenhoekziekenhuis

location_facility: Allina Health Systems dba Virginia Piper Cancer Institute

location_facility: Medical Oncology Hematology Consultants Helen F Graham Cancer Center

location_facility: University of Louisville James Graham Brown Cancer Center

location_facility: UniversitÃ¤tsklinikum Carl Gustav Carus der Technischen UniversitÃ¤t Dresden

location_facility: IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"

location_facility: Baylor Scott and White Research Institute

location_facility: Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie â€" Panstwowy Instytut Badawczy

location_facility: Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

location_facility: Centre Hospitalier Universitaire de Nantes, HÃ´pital HÃ´tel Dieu

location_facility: Centre Hospitalier Universitaire de Bordeaux - HÃ´pital Saint AndrÃ©

location_facility: United States Oncology Regulatory Affairs Corporate Office

location_facility: Szpital Kliniczny im Heliodora Swiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Pozn

location_facility: Uniwersyteckie Centrum Kliniczne Centrum Medycyny Nieinwazyjnej

location_facility: Centre Hospitalier Universitaire de Grenoble - Hopital Nord Michallon

title: Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy

ipd_sharing_description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

location_country:
Germany
Italy
Poland
United Kingdom
Australia
Netherlands
United States
Spain
Greece
Canada
France


title: A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

summary: This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue in patients with NPM1-m AML.

ReferenceCitation: Sasca D, Guezguez B, Kuhn MWM. Next generation epigenetic modulators to target myeloid neoplasms. Curr Opin Hematol. 2021 Sep 1;28(5):356-363. doi: 10.1097/MOH.0000000000000673.

publisher_dissemination: Wolters Kluwer Health

ReferenceCitation: Jimenez JA, Apfelbaum AA, Hawkins AG, Svoboda LK, Kumar A, Ruiz RO, Garcia AX, Haarer E, Nwosu ZC, Bradin J, Purohit T, Chen D, Cierpicki T, Grembecka J, Lyssiotis CA, Lawlor ER. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma. Mol Cancer Res. 2021 Jul;19(7):1182-1195. doi: 10.1158/1541-7786.MCR-20-0679. Epub 2021 Mar 19.

oa_colors: green other

version: acceptedVersion

license: cc-by

license_normalized: cc-by

repositories_concat: PubMed Central;figshare.com

publisher_dissemination: American Association for Cancer Research

ipd_sharing: Undecided

lead_sponsor: Kura Oncology, Inc.

location_country:
Germany
Italy
United States
Spain
Canada
France

location_facility: University of Maryland Greenebaum Comprehensive Cancer Center

location_facility: Hospital Universitari i Politecnic La Fe

location_facility: Indiana University Melvin and Bren Simon Comprehensive Cancer Center

location_facility: IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"

location_facility: Roswell Park Comprehensive Cancer Center

location_facility: Weill Cornell Medical College - NY Presbyterian Hospital

location_facility: Oklahoma University Health - Stephenson Cancer Center

location_facility: Institute of Hematology and Medical Oncology "L. and A. Seragnoli"

location_facility: Hospital Universitario Central de Asturias

location_facility: Institution Fondazione Policlinico Tor Vergata

location_facility: Hackensack University Medical Center - John Theurer Cancer Center

location_facility: Harold C. Simmons Comprehensive Cancer Center - UT Southwestern Medical Center

location_facility: CHU de Quebec - Universite Laval, Hopital de l'Enfant - Jesus


title: International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh)

acronym: AboLiSh

summary: The purpose of the protocol is to assess the longitudinal attainment of person-centered and function related goals of patients who receive AbobotulinumtoxinA (aboBoNT-A) injections for adult lower limb spasticity over a period of 16 months.

study_type: Observational

time_perspective: Prospective

lead_sponsor: Ipsen

location_country:
Germany
Italy
Poland
Australia
Brazil
United States
Canada
Russian Federation
France

location_facility: Centre Hospitalier Regional Universitaire (CHRU) de Lille - Hopital Pierre Swynghedauw - Neurology

location_facility: Rancho Los Amigos National Rehabilitation Center (RLANRC) - Neurology

location_facility: Pavlov First Saint-Petersburg State Medical University - Neurology

location_facility: Yeshiva University - Albert Einstein College of Medicine - Montefiore Medical Center (MMC) - Neurology

location_facility: Università Degli studi della Campania - Luigi Vanvitelli - Neurologica

location_facility: River Valley Health - Stan Cassidy Foundation - Stan Cassidy

location_facility: Medical College of Wisconsin - Froedtert Hospital

location_facility: Wake Forest University Baptist Medical Center

location_facility: Wojew. Wielospecjalistyczne Centrum Onkologii i Traumatologii im.M.Kopernika w Lodzi

location_facility: SAHI Interregional Clinical Diagnostic Center

location_facility: Hospital de Base de São José do Rio Preto at Centro Integrado de Pesquisa (CIP) - Neurology

location_facility: Bekhterev National Research Medical Center for Psychiatry

location_facility: FGBOU VO "Ural state medical university"

location_facility: Beaumont Hospital, Grosse Pointe - Neurology

location_facility: PO Villa Sofia, AO Ospedali Riuniti Villa Sofia-Cervello

location_facility: Mazowiecki Szpital Brodnowski w Warszawie Sp. z o.o. Brodnowskie Centrum Kliniczne Poliklinika Brodnowskiego Centrum Klinicznego

location_facility: Federal State Budgetary Institution "All-Russian Center for Emergency Medicine and Medical Radiology named after A.M. Nikiforov" of the EMERCOM of Russia

location_facility: Neurologie und Psychosomatik am Wittenbergplatz

location_facility: Dayton Center for Neurological Disorders

location_facility: Kansas City Bone and Joint Clinic, P.A. (KCBJ) - Overland Pa

location_facility: Istituto Scientifico di Riabilitazione di Veruno, Fondazione

location_facility: Medizinische Hochschule Hannover - Neurology Neurologische Poliklinik

location_facility: Wojewódzki Szpital Specjalistyczny we Wrocławiu

location_facility: Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto (HCFMRP) - Neurology

location_facility: MedStar National Rehabilitation Hospital

location_facility: Centre Hospitalier Universitaire De Reims - Hopital Maison B

location_facility: Good Shepherd Rehabilitation Hospital - Neurology

location_facility: The University of Utah School of Medicine

location_facility: Universita degli Studi di Verona - Centro di Ricerca in Riabilitazione Neuromotoria e Cognitiva (CRRNC) - Neurology

location_facility: National Medical Research Treatment and Rehabilitation Center of the Ministry of Health of Russia

location_facility: Regional state budget health institution "City Hospital № 5"


title: Performance Evaluation of the VIDAS TB-IGRA Assay.

summary: This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection. This study is designed to assess (1) the sensitivity of this assay, (2) its percent agreement with other diagnostic tests, (3) its measurement precision , and (4) any potential interference of the presence of other non-tuberculosis mycobacterial bacterial infections with this assay.

time_perspective: Cross-Sectional

lead_sponsor: BioMérieux

location_country:
Italy
India
United Kingdom
Brazil
Mexico
United States
South Africa
Georgia
France

location_facility: TASK Applied Science, Delft Day Hospital Premises

location_facility: National Center for Tuberculosis and Lung Disease

location_facility: Autonomous University of Baja California

location_facility: University of Cape Town Centre for Lung Infection and Immunity

location_facility: Universidade Federal Da Grande Dourados (UFGD)

location_facility: Universidade Federal de Mato Grosso do Sul (UFMS)

intervention_type: Diagnostic Test


title: An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations

summary: The purpose of this study was to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various clinical stages of disease progression and prior treatments.

lead_sponsor: Basilea Pharmaceutica

location_country:
Germany
Italy
Poland
Hungary
United Kingdom
Australia
Switzerland
Austria
United States
Korea, Republic of
Spain
Czechia
Canada
France

location_facility: Hospital Universitario HM Sanchinarro CIOCC

location_facility: IRCCS - Istituto Europeo di Oncologia IEO

location_facility: Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH) - Universitaetsklinik fuer Urologie

location_facility: University of Texas Southwestern Medical Center (UTSWMC)

location_facility: Ballarat Oncology & Haematology Services

location_facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

location_facility: Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)

location_facility: ASST Valtellina e Alto Lario - UOC Oncologia Medica Ospedale di Sondrio

location_facility: Medical Oncology - Pitié-Salpêtrière Hopital

location_facility: Fondazione IRCCS Istituto Nazionale dei Tumori

location_facility: Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte

location_facility: Seoul National University Bundang Hospital

location_facility: Medical Oncology Associates PS (dba Summit Cancer Centers)

location_facility: Seoul St. Marys Hospital Catholic University of Korea

location_facility: Englander Institute Weill Cornell Medicine

location_facility: Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego

location_facility: Marques de Valdecilla University Hospital

location_facility: Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o., 04-073, Warszawa, Poland


acronym: RECLAIIM

lead_sponsor: CSL Behring

summary: This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder status based on Total Improvement Score (TIS) assessments.

location_facility: 3800132 - Universitaria Vittorio Emanuele

location_facility: 2760273 - Hautklinik des Uni-Klinikums Erlangen

location_facility: 2760201 - Medizinische Hochschule Hannover (MHH)

location_facility: 2500188 - Centre Hospitalier Regional Universitaire de Lille

location_facility: 8401473 - RecioMed Clinical Research Network, Inc.

location_facility: 4840082 - CINTRE, Centro de Investigacion y Tratamiento Reumatologico S.C.

location_facility: 2760271 - Universitatsklinikum Carl Gustav Carus TU Dresden

location_facility: 8401152 - The University of Kansas Medical Center

location_facility: 8401115 - The University of Texas Medical School at Houston

location_facility: 3920087 - Wakayama Medical University Hospital

location_facility: 2760211 - Charité - Universitätsmedizin Berlin

location_facility: 3920097 - Tokyo Women's Medical University Hospital

location_facility: 6430123 - Yaroslavl Oblast Clinical Hospital

location_facility: 8401486 - Oregon Health and Science University

location_facility: 8401129 - UCLA - Rheumatology Los Angeles

location_facility: 6160104 - Zespol Poradni Specjalistycznych REUMED, ONYKSOWA Filia nr 2

location_facility: 7240086 - Complejo Hospitalario Universitario A Coruña

location_facility: 0320083 - Hospital Italiano de Buenos Aires

location_facility: 3800134 - Azienda Ospedaliero Universitaria Pisana

location_facility: 0320077 - Centro Medico Privado de Reumatolgia

location_facility: 3920125 - Tokyo Medical And Dental University Medical Hospital

location_facility: 6430120 - St. Petersburg City Rheumatological Hospital 25

location_facility: 2500146 - CHU De Dijon Hopital Du Bocage

location_facility: 0560056 - Universitair Ziekenhuis Leuven

location_facility: 3800133 - Universita degli Studi Di Brescia - Azienda Ospedaliera Spedali Civili di Brescia

location_facility: 8040058 - State Institution National Scientific Center Strazhesko

location_facility: 8040057 - Khmelnitskiy Regional Hospital

location_facility: 4840084 - Centro de Alta Especialidad en Reumatologia e Investigacion del Potosí, S.C.

location_facility: 0560050 - Ghent Universit Hospital (UZ Gent)

location_facility: 7240011 - Hospital Universitario Valle de Hebron

location_facility: 8040055 - Mechnikov Institute of Microbiology and Immunology

location_facility: 8040051 - Kyiv Railway Clinical Hospital No.2

location_facility: 2760212 - University Hospital Of Tuebingen

location_facility: 2500144 - Hopitaux Universitaire de Strasbourg

location_facility: 3920086 - St. Marianna University Hospital

location_facility: 7560033 - University Hospital Bern Inselspital

location_facility: 8401474 - West Tennessee Research Institute, LLC

location_facility: 8401117 - Arizona Arthritis & Rheumatology Research

location_facility: 3920091 - Nippon Medical School Hospital

location_facility: 4840081 - Centro Integral en Reumatologia, SA de CV

location_facility: 3800139 - Universita degli Studi Firenze

location_facility: 6430124 - ORIS Firm Limited Liability Company

location_facility: 8401107 - Morsani Center for Advanced Health Care (CAHC)

location_facility: 0560048 - Universitair Ziekenhuis (UZ) Leuven

title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults With Dermatomyositis (DM) - The RECLAIIM Study

ipd_sharing_description:
CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.

If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

location_country:
Germany
Italy
Poland
Hungary
Argentina
United Kingdom
Japan
Switzerland
Mexico
Belgium
United States
Spain
Ukraine
Russian Federation
France


lead_sponsor: Eisai Inc.

summary: The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).

location_facility: University Hospitals Cleveland Medical Center

location_facility: Centre Hospitalier Universitaire de Toulouse

location_facility: Children's Hospital of Richmond at VCU - CHoR-PIN

location_facility: Kleinwachau Saechsisches Epilepsiezentrum Radeberg Gemeinnuetzige Gmbh

location_facility: Hospital General Universitario Gregorio Marañón

location_facility: Wake Forest Baptist Medical Center - PPDS

location_facility: Nemours Foundation Alfred Dupont Children's Hospital

location_facility: Centro Medico Teknon - Grupo Quironsalud

location_facility: Meridian Clinical Research-(Savannah Georgia)

location_facility: Hopitaux de Paris CHU Hopital Robert Debre - Inserm U676

location_facility: Pediatric Epilepsy and Neurology Specialists

location_facility: Hôpital Universitaire des Enfants Reine Fabiola

title: An Open-Label Study With Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhood Epilepsy

ipd_sharing_description: Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

location_country:
Germany
Denmark
Belgium
United States
Spain
Czechia
France


acronym: ASSURE

lead_sponsor: AstraZeneca

summary: This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: treatment-naive (TN), relapsed/refractory (R/R), and prior ibrutinib therapy. For this study, participants in the UK will be enrolled ONLY into the R/R cohort or the prior ibrutinib cohort. Participants in the US will be enrolled ONLY into the TN or R/R cohort. Participants will remain on study intervention until completion of 48 cycles (28 days per cycle), or until study intervention discontinuation due to, for example disease progression, or toxicity, withdrawal of consent, loss to follow-up, death, or study termination by the sponsor whichever occurs first. The duration of the study will be approximately 72 months from the first participant enrolled. This duration includes an estimated 24-month recruitment time and an assumed 48 cycles of study intervention (28 days per cycle); additional study time will be accrued during the Disease Follow up period for those participants remaining on study intervention after completion of 48 cycles prior to the final data cutoff (DCO) (the amount of time will vary by participant).

sponsor_collaborators: AstraZeneca Parexel

title: A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.

ipd_sharing_description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

location_country:
Finland
Germany
Italy
Norway
United Kingdom
Denmark
Australia
Brazil
Netherlands
Sweden
United States
Korea, Republic of
Spain
Taiwan
Canada
Russian Federation
France


title: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma

summary: This is a study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS).

ReferenceType: result

ReferenceCitation: Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klumpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Erratum In: Lancet. 2023 Sep 16;402(10406):964.

repository_institution: The University of Manchester - Research Explorer

repository_normalized: Pure (Denmark)

repositories_concat: Pure (Denmark)

repositories_institution: The University of Manchester - Research Explorer

lead_sponsor: Merck Sharp & Dohme LLC

location_country:
Germany
Ireland
New Zealand
Argentina
Australia
Brazil
Japan
Thailand
Turkey
Chile
Canada
France
Hong Kong
United States
Belgium
China
Malaysia
Italy
United Kingdom
Netherlands
Korea, Republic of
Spain
Taiwan
Israel

location_facility: UZA University Hospital Antwerp ( Site 0202)

location_facility: Azienda Ospedaliera Universitaria di Verona ( Site 0334)

location_facility: Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0506)

location_facility: Hospital de Caridade de Ijui ( Site 0602)

location_facility: The First Hospital of Jilin University ( Site 0131)

location_facility: University of Oklahoma- Stephenson Oklahoma Cancer Center ( Site 0055)

location_facility: A.P.H. Paris, Hopital Beaujon ( Site 0247)

location_facility: St Vincents University Hospital ( Site 0521)

location_facility: Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0180)

location_facility: Chonnam National University Hwasun Hospital ( Site 0837)

location_facility: Hospital de Clinicas de Porto Alegre ( Site 0610)

location_facility: Harbin Medical University Cancer Hospital ( Site 0133)

location_facility: Pamela Youde Nethersole Eastern Hospital ( Site 0857)

location_facility: Winthrop University Hospital ( Site 0059)

location_facility: Gazi Universitesi Tip Fakultesi ( Site 0496)

location_facility: Princess Margaret Hospital. ( Site 0856)

location_facility: Erciyes Universitesi Tip Fakultesi ( Site 0500)

location_facility: The Cancer Institute Hospital of JFCR ( Site 0082)

location_facility: Klinikum der Ludwig - Maximilian Universitat Munchen ( Site 0264)

location_facility: CHU Clermont-Ferrand - Site Estaing ( Site 0249)

location_facility: Policlinico S. Orsola-Malpighi ( Site 0333)

location_facility: Ajou University Hospital, Clinical Research Center ( Site 0838)

location_facility: Hacettepe University Faculty of Medicine ( Site 0498)

location_facility: Royal Marsden NHS Foundation Trust ( Site 0535)

location_facility: Universitair Medisch Centrum Utrecht ( Site 0351)

location_facility: Centro Investigación del Cáncer James Lind ( Site 0622)

location_facility: Maharaj Nakorn Chiang Mai Hospital ( Site 0887)

location_facility: Hospital Nossa Senhora da Conceicao ( Site 0601)

location_facility: National Hospital Organization Kyushu Cancer Center ( Site 0078)

location_facility: University of Alabama at Birmingham Comprehensive Cancer Ctr ( Site 0016)

location_facility: Korea University Guro Hospital ( Site 0832)

location_facility: Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0580)

location_facility: China Medical University Hospital ( Site 0862)

location_facility: Universitaetsklinikum Aachen AOER ( Site 0275)

location_facility: Associacao Hospitalar Moinhos de Vento ( Site 0599)

location_facility: University of California - San Francisco ( Site 0030)

location_facility: The Third Xiangya Hospital of Central South University ( Site 0157)

location_facility: Winship Cancer Institute of Emory University ( Site 0013)

location_facility: National Cancer Center Hospital East ( Site 0081)

location_facility: Universitaetsklinikum Magdeburg A.o.R. ( Site 0271)

location_facility: McGill University Health Centre ( Site 0179)

location_facility: Azienda Ospedaliero Universitaria Pisana ( Site 0326)

location_facility: Fudan University Shanghai Cancer Center ( Site 0160)

location_facility: Northwest Georgia Oncology Centers PC ( Site 0045)

location_facility: Osaka International Cancer Institute ( Site 0084)

location_facility: Pontificia Universidad Catolica de Chile ( Site 0620)

location_facility: Hospital General Universitario Gregorio Maranon ( Site 0433)

location_facility: The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 0839)

location_facility: Fundacion Arturo Lopez Perez FALP ( Site 0623)

location_facility: University Hospital Coventry and Warwickshire NHS Trust ( Site 0518)

location_facility: CHU de Montpellier - Hopital Saint-Eloi ( Site 0248)

location_facility: ASST Grande Ospedale Metropolitano Niguarda ( Site 0332)

location_facility: Universitaetsklinikum Essen ( Site 0273)

location_facility: Seoul National University Bundang Hospital ( Site 0833)

location_facility: CHU Bordeaux Haut-Leveque Centre Francois Magendie ( Site 0245)

location_facility: Koo Foundation Sun Yat-Sen Cancer Center ( Site 0863)

location_facility: Severance Hospital Yonsei University Health System ( Site 0836)

location_facility: Chang Gung Medical Foundation. Linkou ( Site 0853)

location_facility: Mid North Coast Cancer Institute ( Site 0708)

location_facility: University of California San Diego Moores Cancer Center ( Site 0008)

location_facility: Hunan Provincial People Hospital ( Site 0142)

location_facility: Oncobio Servicos de Saude SA ( Site 0604)

location_facility: Fujian Provincial Cancer Hospital ( Site 0154)

location_facility: Royal Free London NHS Foundation Trust ( Site 0520)

location_facility: West China Hospital of Sichuan University ( Site 0147)

location_facility: Aichi Cancer Center Hospital ( Site 0080)

location_facility: Hospital Universitario HM Sanchinarro ( Site 0435)

location_facility: Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0609)

location_facility: Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0038)

location_facility: UCLA Hematology/Oncology - Santa Monica ( Site 0014)

location_facility: National Cheng Kung University Hospital ( Site 0864)

location_facility: Baskent University Adana Training Hospital ( Site 0499)

location_facility: Saint Francis Health System ( Site 0051)

location_facility: Chungnam National University Hospital ( Site 0840)

location_facility: Hospital Regional Universitario Carlos Haya ( Site 0431)

location_facility: Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0865)

location_facility: Western Health-Sunshine Hospital ( Site 0709)

location_facility: Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0182)

location_facility: University of Colorado Hospital ( Site 0011)

location_facility: Taipei Veterans General Hospital ( Site 0861)

location_facility: Erasmus University Medical Center ( Site 0352)

location_facility: Universitaetsklinikum Koeln ( Site 0274)

location_facility: Hadassah Ein Karem - Sharett Institute of Oncology ( Site 0309)

location_facility: Charite - Universtitatsmedizin Berlin CCM ( Site 0269)

location_facility: Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0495)

location_facility: Institut Kanser Negara - National Cancer Institute ( Site 0767)

location_facility: Tianjin Medical University Cancer Institute & Hospital ( Site 0155)

location_facility: University Malaya Medical Centre ( Site 0770)

location_facility: Medizinische Hochschule Hannover ( Site 0265)

location_facility: The First Affiliated Hospital of Xi an Jiaotong University ( Site 0145)

location_facility: Pantai Hospital Kuala Lumpur ( Site 0771)

location_facility: OHSU Center for Health & Healing ( Site 0044)

location_facility: Maastricht University Medical Centre ( Site 0347)

location_facility: Kyungpook National University Chilgok Hospital ( Site 0834)

location_facility: Gallipoli Medical Research Foundation ( Site 0705)

location_facility: Hospital Universitario General de Asturias ( Site 0434)

location_facility: Policlinico Universitario Campus Biomedico ( Site 0328)

location_facility: Columbia University/Herbert Irving Cancer Center ( Site 0009)

location_facility: Staedtisches Klinikum Dresden ( Site 0272)

location_facility: Universitaetsklinikum Hamburg-Eppendorf ( Site 0268)

location_facility: Universita Cattolica del Sacro Cuore - Policlinico Gemelli ( Site 0329)

location_facility: A.O. di Rilievo Nazionale e di alta Specializzazione Garibaldi ( Site 0330)

location_facility: Peking Union Medical College Hospital ( Site 0150)

location_facility: King Chulalongkorn Memorial Hospital ( Site 0884)

location_facility: The Christie NHS Foundation Trust ( Site 0537)

location_facility: Inonu Universitesi Medical Fakultesi ( Site 0501)

location_facility: Hospital Paulistano - Amil Clinical Research ( Site 0603)

location_facility: CHA Bundang Medical Center CHA University ( Site 0835)

location_facility: Kobe City Medical Center General Hospital ( Site 0087)

location_facility: Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0158)

location_facility: First Affiliated Hospital of The Third Military Medical University ( Site 0130)

location_facility: Centro Oncologico Riojano Integral ( Site 0584)

location_facility: Tallaght University Hospital ( Site 0522)

location_facility: Izmir Medical Park Hospital Department of Medical Oncology ( Site 0502)

location_facility: Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 0525)

location_facility: Hospital General Universitari Vall d Hebron ( Site 0432)

location_facility: Abdurrahman Yurtaslan Onkoloji Hastanesi ( Site 0494)

location_facility: Instituto COI de Pesquisa Educacao e Gestao ( Site 0606)

location_facility: National Taiwan University Hospital ( Site 0860)

location_facility: Guangdong Provincial People s Hospital ( Site 0161)

location_facility: Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0607)

location_facility: The First Affiliated Hospital Zhejiang University ( Site 0136)

location_facility: Zhongshan Hospital Fudan University ( Site 0129)


title: A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant Tumors

summary: The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.

lead_sponsor: Bristol-Myers Squibb

location_country:
Italy
Argentina
United States
Spain
Chile
Canada
France

location_facility: Assistance Publique Hôpitaux de Marseille - Hôpital Nord

location_facility: University of Florida College of Medicine

location_facility: University of California, Irvine (UCI) Health - UC Irvine Medical Center

location_facility: Fondazione IRCCS Istituto Nazionale dei Tumori

location_facility: University of California, Irvine (UCI) Health Cancer Center - Newport/Costa Mesa

location_facility: Hospices Civils de Lyon - Hopital Louis Pradel

location_facility: Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes

location_facility: Centre Hospitalier intercommunal de Toulon La Seyne sur Mer

location_facility: Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore


lead_sponsor: Novartis Pharmaceuticals

summary: A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

location_facility: Childrens National Hospital CQTI571A2306

title: An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)

ipd_sharing_description:
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

location_country:
Finland
Germany
Argentina
Australia
Brazil
Japan
Czechia
Canada
France
Denmark
United States
Belgium
Italy
United Kingdom
Sweden
Netherlands
Spain
Russian Federation
Israel


title: A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients With Brain Contusion

acronym: ASTRAL

summary:
The primary objective is to determine if BIIB093 reduces brain contusion expansion by Hour 96 when compared to placebo.

The secondary objectives are to evaluate the effects of BIIB093 on acute neurologic status, functional outcomes, and treatment requirements, to further differentiate the mechanism of action of BIIB093 on contusion expansion by examining differential effects on hematoma and edema expansion, and to determine if BIIB093 improves survival at Day 90 when compared to placebo.

ipd_sharing_description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

lead_sponsor: Biogen

location_country:
Germany
Italy
France
Japan
United States
Spain
Israel

location_facility: Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda)

location_facility: Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona

location_facility: The University of Texas Health Science Center at Houston

location_facility: Scottsdale Healthcare Hospitals d/b/a HonorHealth

location_facility: Virginia Commonwealth University Medical Center

location_facility: ASST Monza - Ospedale San Gerardo di Monza

location_facility: Azienda Ospedaliero Universitaria di Parma

location_facility: Complejo Hospitalario Universitario de Santiago

location_facility: Health Corporation of Galilee Medical Center

location_facility: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

location_facility: Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

location_facility: CHU de Brest - Hôpital de la Cavale Blanche

location_facility: University of North Carolina at Chapel Hill

location_facility: CHU Clermont Ferrand - Hopital Gabriel Montpied

location_facility: Groupe Hospitalier Pellegrin - Hôpital Pellegrin

location_facility: Kobe City Hospital Organization Kobe City Medical Center General Hospital

location_facility: Universitaetsklinikum Schleswig-Holstein - Campus Kiel

location_facility: University of Cincinnati College of Medicine


lead_sponsor: Zogenix, Inc.

summary: This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy

sponsor_collaborators: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

title: An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome

ipd_sharing_description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

location_country:
Germany
Italy
Poland
United Kingdom
Denmark
Australia
Sweden
Netherlands
Mexico
Belgium
United States
Spain
Canada
France


summary: The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It was hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days.

location_facility: The University of Texas MD Anderson Cancer Center ( Site 0154)

location_facility: Centre Hospitalier Universitaire Dupuytren ( Site 0182)

location_facility: Indiana Blood and Marrow Transplantation ( Site 0175)

location_facility: Queen Elizabeth University Hospital [Glasgow, UK] ( Site 0096)

location_facility: IRCCS Ospedale San Raffaele ( Site 0051)

location_facility: University of Miami, Sylvester Comprehensive Cancer Center ( Site 0160)

location_facility: Jichi Medical University Hospital ( Site 0123)

location_facility: ASST Spedali Civili di Brescia ( Site 0052)

location_facility: Freeman Hospital Newcastle upon Tyne Foundation NHS Trust ( Site 0092)

location_facility: University of California Davis Medical Center ( Site 0156)

location_facility: Policlinico Universitario Agostino Gemelli ( Site 0055)

location_facility: Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 0121)

location_facility: Memorial Sloan Kettering Cancer Center ( Site 0164)

location_facility: Duke University Medical Center ( Site 0169)

location_facility: John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0174)

location_facility: National Hospital Organization Kumamoto Medical Center ( Site 0122)

location_facility: Fred Hutchinson Cancer Research Center ( Site 0152)

location_facility: Fondazione PTV Policlinico Tor Vergata ( Site 0054)

location_facility: City of Hope National Medical Center ( Site 0158)

location_facility: Universitaetsklinikum Muenster ( Site 0043)

location_facility: Universitaetsklinikum Heidelberg-Medizinische Klinik V ( Site 0042)

title: A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)

primary_purpose: Prevention

location_country:
Germany
Italy
United Kingdom
Japan
United States
France


title: Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer

summary: The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

lead_sponsor: Eli Lilly and Company

location_country:
United Kingdom
Japan
Belgium
United States
Korea, Republic of
Spain
Turkey
France

location_facility: University of Texas MD Anderson Cancer Center

location_facility: Hospital Universitario La Fe de Valencia

location_facility: Hospital Clinico Universitario Virgen de la Victoria

location_facility: Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

location_facility: Grand Hopital de Charleroi-Site Notre-Dame

location_facility: Institut de Cancérologie de l'Ouest Centre René Gauducheau

location_facility: Severance Hospital Yonsei University Health System

location_facility: Centre de Lutte Contre le Cancer Leon Berard

location_facility: Dr.Abdurrahman Yurtaslan Ankara Oncology Training & Res Hosp

location_facility: Levine Cancer Institute- Carolinas Medical Center


title: PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

summary:
This study is a multinational Phase 3, randomized, double-blind, non-inferiority, efficacy and safety study of oral HC-1119 (80 mg/day) versus enzalutamide (160 mg/day) in asymptomatic or mildly symptomatic patients with progressive metastatic castration-resistant prostate cancer (mCRPC).

The following assessment of prostate cancer status will be collected during the course of the trial: soft tissue disease on computed tomography (CT) scan or on magnetic resonance imaging (MRI), bone disease on radionuclide bone scans, FACT-P and EQ-5D, Brief Fatigue Inventory, and PSA.

Throughout the study, safety and tolerability will be assessed by the recording of adverse events, monitoring of vital signs and physical examinations, safety laboratory evaluations, and 12-lead electrocardiograms (ECGs). Blood samples for population pharmacokinetics for HC-1119 and enzalutamide and related metabolites will be collected.

lead_sponsor: Hinova Pharmaceuticals USA, Inc.

location_country:
Finland
Germany
Italy
Poland
United Kingdom
Denmark
Australia
Netherlands
Austria
United States
Spain
Canada
Russian Federation
France

location_facility: Azienda Ospedaliera Universitaria Integrata Di Verona

location_facility: Urology San Antonio Stone Oak, 18915 Meisner Drive

location_facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy

location_facility: Urology Center of Colorado, 2777 Mile High Stadium Circle

location_facility: Federal State Institution Medical Radiology Research Center

location_facility: First St. Petersburg State Medical University n.a. I.P Pavlov

location_facility: Clinical Research Center Spolka z Ograniczona

location_facility: Hopital d'Instruction des Armées de Begin

location_facility: Urologica Praktyka Lekarska Adam Marcheluk

location_facility: Fundacion Instituto Valenciano de Oncologia

location_facility: First Urology PSC, 101 Hospital Boulevard

location_facility: Helsinki University Hospital Comprehensive Cancer Center - PPDS

location_facility: Hospital Universitario Virgen del Rocio - PPDS

location_facility: Hospital Regional Universitario de Malaga - Hospital Civil

location_facility: GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)

location_facility: Centre Jean Bernard Clinique Victor Hugo


title: A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer

summary: The main purpose of the study was to evaluate the safety and tolerability of M7824 in combination with chemotherapy.

ReferenceCitation: Vugmeyster Y, Grisic AM, Wilkins JJ, Loos AH, Hallwachs R, Osada M, Venkatakrishnan K, Khandelwal A. Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1. Cancer Chemother Pharmacol. 2022 Oct;90(4):369-379. doi: 10.1007/s00280-022-04468-6. Epub 2022 Sep 6.

repositories_concat: PubMed Central

ipd_sharing_description: We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

lead_sponsor: EMD Serono Research & Development Institute, Inc.

location_country:
United States
Belgium
France

location_facility: Universitair Ziekenhuis Gent - Medical Oncology

location_facility: University of Maryland - DUPLICATE/Pediatric Surgery

location_facility: Hematology - Oncology Associates of Treasure Coast - Hematology-Oncology Associates of Treasure Coast

location_facility: Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Maison du Ha

location_facility: Centre Georges François Leclerc - Unité de Phase I

location_facility: Baptist Health Lexington Oncology Associates

location_facility: Hôpital de la Timone# - CPCEM CIC - Bat F 1er étage

location_facility: Universitair Ziekenhuis Brussel - Geriatrie

location_facility: California Cancer Associates for Research & Excellence, Inc.

location_facility: Compassionate Care Research Group Inc - Edinger Medical Group, Inc.

location_facility: CHU Poitiers - Hôpital la Milétrie - service d'oncologie médicale